Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies.

Drugs - 1 Jan 2024

Caughey Bennett A, Strickler John H

Abstract excerpt

Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated oncogenes in cancer and the mutational prevalence is especially high in many gastrointestinal malignancies, including colorectal cancer and pancreatic ductal adenocarcinoma. The KRAS protein is a small GTPase that functions as an "on/off" switch to activate downstream signaling, mainly through the mitogen-activated protein kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Colorectal Neoplasms
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38109010
DOI: 10.1007/s40265-023-01980-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies.PMID 38109010Read ↗

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.Semantic proximity Read ↗

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read ↗

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read ↗

Targeting KRAS mutation in gastrointestinal cancersSemantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

Targeting Mutated KRAS Genes to Treat Solid Tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.